Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

0.8441 UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

What Mainz Biomed (NASDAQ: MYNZ) Has Been Up To Recently And Why Frankie Muniz Is A Backer

November 12, 2024

What Mainz Biomed (NASDAQ: MYNZ) Has Been Up To Recently And Why Frankie Muniz Is A Backer

Via News Direct

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

October 21, 2024

From Mainz BioMed NV

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 15, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 15, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 14, 2024

Via Benzinga

Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer ↗

October 10, 2024

On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The large-scale clinical project assessed how personalized cancer therapies could...

Via Benzinga

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

October 08, 2024

GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-Baden

From Mainz BioMed NV

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 07, 2024

Via Benzinga

Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early

October 07, 2024

Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early

Via News Direct

The Covid Era Tech Promises To Reinvent Cancer Treatment ↗

October 01, 2024

Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story.

Via Benzinga

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

October 01, 2024

From Mainz BioMed NV

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 27, 2024

Via Benzinga

Pfizer Advances On Its Cancer Journey ↗

September 20, 2024

On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024...

Via Benzinga

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

September 18, 2024

Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection

From Mainz BioMed NV

Via GlobeNewswire

Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool

September 05, 2024

Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool

Via News Direct

Topics Artificial Intelligence

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

September 04, 2024

PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis

From Mainz BioMed NV

Via GlobeNewswire

Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test

September 03, 2024

Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test

Via News Direct

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

September 03, 2024

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Via News Direct

Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status

July 31, 2024

Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status

Via News Direct

Topics Artificial Intelligence

Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer ↗

July 30, 2024

The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)...

Via Benzinga

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

July 25, 2024

From Mainz BioMed NV

Via GlobeNewswire

Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good ↗

July 10, 2024

This week, Pfizer Inc (NYSE: PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

July 09, 2024

It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning!

Via InvestorPlace

Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket ↗

July 09, 2024

Via Benzinga

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

July 09, 2024

From Mainz BioMed NV

Via GlobeNewswire

Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 08, 2024

Via Benzinga

mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment ↗

July 02, 2024

The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens...

Via Benzinga

Mainz Biomed Provides Half Year 2024 Corporate Update

July 02, 2024

Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study

From Mainz BioMed NV

Via GlobeNewswire

Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight ↗

June 26, 2024

On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt,...

Via Benzinga

Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks

June 21, 2024

Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks

Via News Direct

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.